Atezolizumab: an investigational agent for the treatment of biliary tract cancer

被引:5
作者
Hack, Stephen P. [1 ]
Zhu, Andrew X. [2 ,3 ,4 ]
机构
[1] Genentech Inc, Product Dev Oncol, San Francisco, CA 94080 USA
[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Jiahui Hlth, Jiahui Int Canc Ctr, Shanghai, Peoples R China
关键词
Atezolizumab; biliary tract cancer; cholangiocarcinoma; gallbladder cancer; PD-L1; GROWTH-FACTOR-BETA; PHASE-III TRIAL; DOUBLE-BLIND; OPEN-LABEL; 1ST-LINE TREATMENT; PLUS GEMCITABINE; COMBINATION; CISPLATIN; PLACEBO; CHEMOTHERAPY;
D O I
10.1080/13543784.2021.1974838
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Biliary tract cancers (BTCs) have a dismal prognosis and limited treatment options. The role of immunotherapy in BTC is unclear. BTCs respond poorly to PD-(L)1 blockade, highlighting the need for combination regimens to augment antitumor immunity. Atezolizumab (anti-PD-L1) combined with other therapies is under investigation in advanced BTC. Areas covered This paper provides an overview of the recent progress and future applications of immunotherapy for BTCs and sheds light on the status and therapeutic potential of atezolizumab. We discuss published data for atezolizumab and an examine the rationale and design of ongoing clinical studies. We offer insights and opinions on the future applications and challenges of immunotherapy in BTC. Expert opinion Atezolizumab monotherapy has demonstrated limited antitumor activity in BTC, indicating the need for combination regimens to unlock effective anticancer immunity, and the development of predictive biomarkers to enrich the population. Data for atezolizumab combined with chemotherapy, anti-VEGF agents and other targeted drugs in solid tumors justifies their evaluation in BTC. Several novel atezolizumab-based combinations have been or are currently under investigation in Phase II studies. It is hoped that data from these studies, along with other immunotherapy trials, will provide more effective treatments for patients with BTC.
引用
收藏
页码:1007 / 1015
页数:9
相关论文
共 103 条
[1]   Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [J].
Abou-Alfa, Ghassan K. ;
Macarulla, Teresa ;
Javle, Milind M. ;
Kelley, Robin K. ;
Lubner, Sam J. ;
Adeva, Jorge ;
Cleary, James M. ;
Catenacci, Daniel V. ;
Borad, Mitesh J. ;
Bridgewater, John ;
Harris, William P. ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Whisenant, Jonathan ;
Lowery, Maeve A. ;
Goyal, Lipika ;
Shroff, Rachna T. ;
El-Khoueiry, Anthony B. ;
Fan, Bin ;
Wu, Bin ;
Chamberlain, Christina X. ;
Jiang, Liewen ;
Gliser, Camelia ;
Pandya, Shuchi S. ;
Valle, Juan W. ;
Zhu, Andrew X. .
LANCET ONCOLOGY, 2020, 21 (06) :796-807
[2]   Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].
Abou-Alfa, Ghassan K. ;
Sahai, Vaibhav ;
Hollebecque, Antoine ;
Vaccaro, Gina ;
Melisi, Davide ;
Al-Rajabi, Raed ;
Paulson, Andrew S. ;
Borad, Mitesh J. ;
Gallinson, David ;
Murphy, Adrian G. ;
Oh, Do-Youn ;
Dotan, Efrat ;
Catenacci, Daniel, V ;
Van Cutsem, Eric ;
Ji, Tao ;
Lihou, Christine F. ;
Zhen, Huiling ;
Feliz, Luis ;
Vogel, Arndt .
LANCET ONCOLOGY, 2020, 21 (05) :671-684
[3]  
Anderson NM, 2020, CURR BIOL, V30, pR921, DOI 10.1016/j.cub.2020.06.081
[4]   Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF) [J].
Arkenau, Hendrik-Tobias ;
Martin-Liberal, Juan ;
Calvo, Emiliano ;
Penel, Nicolas ;
Krebs, Matthew G. ;
Herbst, Roy S. ;
Walgren, Richard A. ;
Widau, Ryan C. ;
Mi, Gu ;
Jin, Jin ;
Ferry, David ;
Chau, Ian .
ONCOLOGIST, 2018, 23 (12) :1407-+
[5]   Transforming Growth Factor-β Signaling in Immunity and Cancer [J].
Batlle, Eduard ;
Massague, Joan .
IMMUNITY, 2019, 50 (04) :924-940
[6]   Immunotherapy in Advanced Biliary Tract Cancers [J].
Boileve, Alice ;
Hilmi, Marc ;
Smolenschi, Cristina ;
Ducreux, Michel ;
Hollebecque, Antoine ;
Malka, David .
CANCERS, 2021, 13 (07)
[7]   Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial [J].
Boileve, Alice ;
Hilmi, Marc ;
Gougis, Paul ;
Cohen, Romain ;
Rousseau, Benoit ;
Blanc, Jean-Frederic ;
Ben Abdelghani, Meher ;
Castanie, Helene ;
Dahan, Laetitia ;
Tougeron, David ;
Metges, Jean-Philippe ;
Tournigand, Christophe ;
Garcia-Larnicol, Marie-Line ;
Vernerey, Dewi ;
Turpin, Anthony ;
Neuzillet, Cindy .
EUROPEAN JOURNAL OF CANCER, 2021, 143 :55-63
[8]   Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth [J].
Chen, Xin ;
Amar, Norhan ;
Zhu, Yuankui ;
Wang, Chunguang ;
Xia, Chunjiao ;
Yang, Xiaoqing ;
Wu, Dongde ;
Feng, Mingqian .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[9]  
de Olza MO, 2020, LANCET ONCOL, V21, pE419, DOI 10.1016/S1470-2045(20)30234-5
[10]   Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy [J].
Dennison, Lauren ;
Ruggieri, Amanda ;
Mohan, Aditya ;
Leatherman, James ;
Cruz, Kayla ;
Woolman, Skylar ;
Azad, Nilofer ;
Lesinski, Gregory B. ;
Jaffee, Elizabeth M. ;
Yarchoan, Mark .
CANCER IMMUNOLOGY RESEARCH, 2021, 9 (10) :1187-1201